Orf

Back

Background

Orf, also known as ecthyma contagiosum, contagious pustular dermatitis, infectious labial dermatitis, scabby mouth, or sore mouth, is a viral disease first described in humans in 1934 by Newson and Cross.[1] It is endemic in sheep and goat herds worldwide but can be found in other ruminants. It causes skin lesions on lips, muzzle, ears, eyelids, nostrils, and, less commonly in genitalia, udders, and feet of infected animals.[2] Orf is transmitted to humans through direct contact with an infected animal or, less commonly, contaminated fomites. Although extremely rare, human-to-human transmission has been reported. Lesions occur most commonly on the hands. Orf is frequently seen in ranching communities[3, 4] and in those who process the animals for consumption. It typically has a self-limited course with spontaneous resolution in 4-8 weeks after progressing through distinct stages. A typical clinical presentation of a reddish weeping nodule of orf located on the thumb is shown in the image below.



View Image

An early lesion of orf (papular stage).

Pathophysiology

Orf is caused by infection with the orf virus that belongs to the Parapoxvirus genus, which also includes the milker's nodule virus.[5] Parapoxvirus is a member of the family Poxviridae, which are double-stranded DNA viruses known to be the largest of all animal viruses.[6]

The orf virus is a cylindrical virus measuring 260 X 160 nm. Its surface tubules form a long crisscross design that is seen on negatively stained preparations by electron microscopy. This virus resists physical damage and persists through the winter months on hedges, feeding troughs, fences, harnesses, and barns.[7] It can remain viable on the wool of animals and on items that remain at room temperature for years.[8, 9]

The orf virus is able to produce a homolog of anti-inflammatory cytokine, interleukin (IL)‒10, which contributes to localized suppression of immunity.[10, 11] Orf also produces protein that inhibits IL-2 and granulocyte macrophage-colony stimulating factor and a vascular endothelial growth factor homolog.[12] The B2L major envelope protein has lipase activity and immunomodulating properties.[13]

Orf is transmitted by direct contact inoculation usually via a wound in the skin. Humans acquire the infection from contact with infected animals, carcasses, or contaminated, nonliving material. Orf is very common among shepherds, veterinary surgeons, and farmers' wives who bottle-feed young lambs, as well as in butchers, cooks, and meat porters from handling infected carcasses. It has been also linked to exposures at petting zoos and livestock shows.[14]

Autoinoculation to the genital area and face can occur, but human-to-human transmission is rare and there are reports in the literature of six possible cases.[7, 15, 16, 17] Nosocomial human-to-human was reported in patients on a burn unit.[18]

Epidemiology

Frequency

The majority of orf infections go unreported because the disease is self-limited, and those infected are able to recognize orf and do not seek medical attention.

Race

No racial predilection exists for orf.

Sex

Orf occurs more commonly in men owing to the fact that men more likely to have an occupational exposure (eg, ranching, veterinary medicine, animal slaughter).[19]

Age

Lesions are more common in adults but have been report in children with exposure to animals on farms and petting zoos.[19]

Occupation

Orf is an occupational hazard of ranchers, veterinarians, butchers, shearers, and shepherds.

Religion

Orf has been reported in people who prepare sheep or goats for religious feasts. The most common is the Muslim practice of Eid ul-Adha, but it also has been reported in Jewish Passover and Christian Easter celebrations.[20, 21, 22, 23]

Prognosis

The prognosis of orf is excellent. The orf lesions usually heal completely with no scarring in about 35 days (4-8 wk). Scarring can occur if secondary infection or trauma to the lesion occurs.

Immunocompromised patients with orf can have progressive, destructive lesions requiring medical interventions such as antiviral therapy, reduction of immunosuppression, and surgical debridement. However, reports exist of immunosuppressed individuals with large, fungating lesions that have been refractory to treatment and required amputation.

Mortality from orf has not been reported.

Patient Education

Most patients infected with orf are farmers or people who handle animals; therefore, they are usually familiar with the disease. Those who are unacquainted with this condition must be reassured that the disease typically runs a benign self-limited course, and they should be instructed on proper wound care. They must also be informed that recurrences due to repeat infection may occur but generally result in lesions that are less pronounced than the primary infection.

Further information is available for on orf infections in both humans and animals at the US Centers for Disease Control and Prevention (CDC) Web site.[24] See Orf Virus (Sore Mouth Infection).

History

Orf occurs in humans with an occupational or household exposure to the virus via infected animals or fomites. The hands are where 95% of cases occur (see the image below).[25] The lesions may be pruritic and are generally painless. If the lesions are painful, then secondary infection should be suspected.[26] With orf, a low-grade fever may occur but usually subsides within 3-4 days. Systemic symptoms such as lymphadenopathy, erysipelaslike lesions, and erythema multiforme can occur in up to one third of cases.[27] Large, fungating orf lesions or multiple lesions have been reported in patients who are immunosuppressed, burn patients, atopic dermatitis patients, and one patient with scleroderma.[26, 28]



View Image

A classic location of orf on the index finger.

Physical Examination

Orf appears as a solitary lesion or as a few lesions on the fingers, hands, or forearms, and orf has even been reported on the face, scalp, and groin.[29] The orf lesion starts as a small, firm, red-to-blue papule then progresses through a series of 6 stages.  The fully developed orf lesion is typically 2-3 cm in diameter, but it may reach 5 cm.

After incubation of 3-7 days, the orf infection goes through six clinical stages, each lasting about 1 week, as follows:

Complications

Orf infections can be associated with fever, lymphangitis, lymphadenopathy, erythema multiforme,[30, 31] and secondary bacterial infections. Papulovesicular eruptions and bullous pemphigoid‒like eruptions are very rare complications of orf.[32, 33, 34] Blindness has been reported when the diseases affects the eye.[35] Immunocompromised patients can develop giant orf, multiple lesions, and recurrent lesions; these can take longer or may fail to spontaneous resolve.[36] A swan-neck deformity of the index finger has also been reported.[23] Pregnancy and fetal development have not been reported to be adversely affected by this viral infection.[37]



View Image

Orf lesion (arrow) associated with erythema multiforme.

Dermoscopy

Depending on the stage of the lesion, dermoscopic examination can demonstrate various findings to include a well-defined nodule with a central crust, white structureless areas, a blue-gray area, orange-yellow streaks, white shiny streaks, dotted vessels, hairpin vessels, an erythematous ring, a yellow-white ring, and a fine peripheral scale.[38, 39]

Laboratory Studies

The diagnosis of orf is usually made based on the history of contact with infected animal and the presence of a typical clinical lesion, but there are laboratory studies that can aid in the diagnosis.

Polymerase chain reaction (PCR) can definitively identify the virus and is available from the US Centers for Disease Control and Prevention (CDC) (telephone 404-639-4129).[41, 42, 43] Clinicians should contact their state health department to coordinate PCR testing.

Conventional histopathology of an orf skin biopsy may be of significant diagnostic value (see below).

No serologic tests are routinely performed for orf, but a detectable antibody response may be present.[44] Serology cannot distinguish orf virus from other parapoxviruses such as paravaccinia (pseudocowpox) virus.

Confirmation of the clinical diagnosis of orf can be made by electron microscopy with negative staining of the crust or a small biopsy specimen. Electron microscopy has also been performed on fluid obtained from the orf lesion.[45] It demonstrates classic ovoid cross-hatched virions but cannot be used to distinguish orf virus from other parapoxviruses.

Tissue culture with passage of the orf virus to sheep cell cultures is an option; however, the growth of the virus is slow and inconstant.

Histologic Findings

The epidermis usually shows marked pseudoepitheliomatous hyperplasia. Necrosis of the epidermis with ulceration occurs in the center of the lesion. The orf viral infection causes intranuclear and intracytoplasmic inclusion bodies with vacuolization and disaggregation of keratinocytes. Pyknosis of individual keratinocytes occurs. A dense inflammatory infiltrate of plasma cells, macrophages, histiocytes, and lymphocytes is also observed in orf.

Medical Care

Although orf is a self-limited disease, symptomatic treatment with moist dressings, local antiseptics, and finger immobilization is helpful. Secondary bacterial infection of orf is not uncommon and must be treated with topical or systemic antibiotics. Several case reports describe orf successfully treated with topical imiquimod resulting in rapid regression of the lesions.[46, 47, 48] Imiquimod has been effective in both immunocompetent and immunocompromised patients. Regimens range from once every other day to twice-daily application topically to the lesion. The use of interferon alfa-2a and 2b has also been reported in refractory giant orf lesions in immunocompromised patients.[49, 50] Reports also describe effective treatment of orf with cidofovir cream and cidofovir intravenously.[51, 52, 53]

Surgical Care

Because of its self-limited nature, surgical procedures are usually reserved for immunocompromised patients who do not respond to conservative measures.[27] Cryotherapy (liquid nitrogen) has been reported to speed the recovery process from orf treatment.[54, 55] Shave excision is a procedure that can be diagnostic and therapeutic for small orf lesions. For large exophytic orf lesions, dissection from the underlying dermis has been performed.[56] If an orf lesion is persistent, curettage and electrodesiccation may be curative. Amputation should only be used as a last resort. Recurrences and delayed healing have been reported after surgical treatment.[19, 50]

Prevention

The best preventive measure in animals is an orf vaccination every 6-8 months. The orf vaccine is an attenuated vaccine, and, therefore, recently vaccinated animals do pose an infection risk to humans.[57] Once an animal is infected, it should be put in isolation.

To prevent infections in humans taking preventive measures is essential. It is recommend to wear nonpermeable rubber or latex gloves when handling sheep or goats, especially if there is a cut or sore present on the mouth/muzzle area. Practice good hand washing with warm soapy water for 20 seconds or by using a waterless alcohol-based hand sanitizer when soap is not available.[24] Protective immunity after infection is incomplete, so reinfection can occur unless precautions are taken.[21]

Patients who are immunosuppressed or persons with compromised skin barriers (eg, trauma, skin disease) must avoid contact with infected animals because they have an increased susceptibility for contracting the orf infection.

Medication Summary

Several case reports describe orf successfully treated with topical imiquimod, interferon alpha-2a, cidofovir cream, and cidofovir intravenously.[46, 47, 48, 51, 52, 53]

Imiquimod (Aldara, Zyclara)

Clinical Context:  Imiquimod induces secretion of interferon alpha and other cytokines; the mechanisms of action are unknown. Use in orf is off-label.

Cidofovir (Vistide)

Clinical Context:  Cidofovir is a nucleotide analog that selectively inhibits viral DNA production in CMV and other herpes viruses. Use in orf is off-label.

Interferon alfa 2b (Interferon alfa-2b, Intron A)

Clinical Context:  Interferon alfa-2b is a protein product manufactured by recombinant DNA technology. Interferon alfa has antiviral, antiproliferative, and antiangiogenic properties, and it stimulates the immune system. Use in orf is off-label.

Author

Aaron Z Hoover, MD, FAAD, Staff Dermatologist/Dermatopathologist, Front Range Dermatology Associates

Disclosure: Nothing to disclose.

Coauthor(s)

Mallory Milroy, Medical Assistant, Surgical Assistant, Histology Technician, Front Range Dermatology Associates

Disclosure: Nothing to disclose.

Specialty Editors

Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Disclosure: Nothing to disclose.

Jeffrey J Miller, MD, Associate Professor of Dermatology, Pennsylvania State University College of Medicine; Staff Dermatologist, Pennsylvania State Milton S Hershey Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Lana H Hawayek, MD, Assistant Professor of Dermatology, Cosmetic Dermatologic Surgery and Laser Specialist, University of Cincinnati, Veterans Affairs Medical Center; Consulting Staff, University Dermatology Consultants

Disclosure: Nothing to disclose.

Nelly Rubeiz, MD, Consulting Staff, Department of Dermatology, American University of Beirut Medical Center; Professor, Department of Dermatology, American University of Beirut, Lebanon

Disclosure: Nothing to disclose.

Shyam Verma, MBBS, DVD, FAAD, Clinical Associate Professor, Department of Dermatology, University of Virginia School of Medicine; Adjunct Associate Professor, Department of Dermatology, State University of New York at Stonybrook School of Medicine; Adjunct Associate Professor, Department of Dermatology, University of Pennsylvania School of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Special thanks to Ms. Carmen Urich, Medical Librarian for Banner Western Division, for helping acquire articles for this publication.

References

  1. Newsome IE, Cross F. Sore mouth in sheep transmissible to man. J AM VET MED ASSOC. 1934. 84:790-802.
  2. Maganga GD, Relmy A, Bakkali-Kassimi L, Ngoubangoye B, Tsoumbou T, Bouchier C, et al. Molecular characterization of Orf virus in goats in Gabon, Central Africa. Virol J. 2016 May 13. 13:79. [View Abstract]
  3. Buchan J. Characteristics of orf in a farming community in mid-Wales. BMJ. 1996 Jul 27. 313(7051):203-4. [View Abstract]
  4. Paiba GA, Thomas DR, Morgan KL, Bennett M, Salmon RL, Chalmers R, et al. Orf (contagious pustular dermatitis) in farmworkers: prevalence and risk factors in three areas of England. Vet Rec. 1999 Jul 3. 145(1):7-11. [View Abstract]
  5. Groves RW, Wilson-Jones E, MacDonald DM. Human orf and milkers' nodule: a clinicopathologic study. J Am Acad Dermatol. 1991 Oct. 25(4):706-11. [View Abstract]
  6. Bodilsen J, Leth S. [Orf Parapoxvirus can infect humans after relevant exposure.]. Ugeskr Laeger. 2013 Apr 15. 175(16):1121-1122. [View Abstract]
  7. Duchateau NC, Aerts O, Lambert J. Autoinoculation with Orf virus (ecthyma contagiosum). Int J Dermatol. 2014 Jan. 53 (1):e60-2. [View Abstract]
  8. Spyrou V, Valiakos G. Orf virus infection in sheep or goats. Vet Microbiol. 2015 Dec 14. 181 (1-2):178-82. [View Abstract]
  9. Poxviruses. Tyring SK. Mucocutaneous Manifestations of Viral Disease. New York, Basel: Marcel Dekker, Inc.; 2002. 51-55.
  10. Erbağci Z, Erbağci I, Almila Tuncel A. Rapid improvement of human orf (ecthyma contagiosum) with topical imiquimod cream: report of four complicated cases. J Dermatolog Treat. 2005. 16 (5-6):353-6. [View Abstract]
  11. Bennett JR, Lateef Z, Fleming SB, Mercer AA, Wise LM. Orf virus IL-10 reduces monocyte, dendritic cell and mast cell recruitment to inflamed skin. Virus Res. 2016 Feb 2. 213:230-7. [View Abstract]
  12. Biyik Ozkaya D, Taskın B, Tas B, Asıran Serdar Z, Demirkesen C, Su O, et al. Poxvirus-induced angiogenesis after a thermal burn. J Dermatol. 2014 Sep. 41 (9):830-3. [View Abstract]
  13. Yogisharadhya R, Kumar A, Ramappa R, Venkatesan G, Bhanuprakash V, Shivachandra SB. Functional characterization of recombinant major envelope protein (rB2L) of orf virus. Arch Virol. 2017 Apr. 162 (4):953-962. [View Abstract]
  14. Lederman ER, Austin C, Trevino I, Reynolds MG, Swanson H, Cherry B, et al. ORF virus infection in children: clinical characteristics, transmission, diagnostic methods, and future therapeutics. Pediatr Infect Dis J. 2007 Aug. 26 (8):740-4. [View Abstract]
  15. Rajkomar V, Hannah M, Coulson IH, Owen CM. A case of human to human transmission of orf between mother and child. Clin Exp Dermatol. 2016 Jan. 41 (1):60-3. [View Abstract]
  16. Bouscarat F, Descamps V. Wife to husband transmission of Ecthyma contagiosum (Orf). IDCases. 2017. 9:28-29. [View Abstract]
  17. Rajkomar V, Hannah M, Coulson IH, Owen CM. A case of human to human transmission of orf between mother and child. Clin Exp Dermatol. 2016 Jan. 41 (1):60-3. [View Abstract]
  18. Midilli K, Erkiliç A, Kuşkucu M, Analay H, Erkiliç S, Benzonana N, et al. Nosocomial outbreak of disseminated orf infection in a burn unit, Gaziantep, Turkey, October to December 2012. Euro Surveill. 2013 Mar 14. 18 (11):20425. [View Abstract]
  19. Caravaglio JV, Khachemoune A. Orf Virus Infection in Humans: A Review With a Focus on Advances in Diagnosis and Treatment. J Drugs Dermatol. 2017 Jul 1. 16 (7):684-689. [View Abstract]
  20. Shahmoradi Z, Abtahi-Naeini B, Pourazizi M, Meidani M. Orf Disease Following "Eid ul-Adha": A Rare Cause of Erythema Multiforme. Int J Prev Med. 2014 Jul. 5 (7):912-4. [View Abstract]
  21. Centers for Disease Control and Prevention (CDC). Human Orf virus infection from household exposures - United States, 2009-2011. MMWR Morb Mortal Wkly Rep. 2012 Apr 13. 61 (14):245-8. [View Abstract]
  22. Veraldi S, Nazzaro G, Vaira F, Çuka E. Presentation of orf (ecthyma contagiosum) after sheep slaughtering for religious feasts. Infection. 2014 Aug. 42 (4):767-9. [View Abstract]
  23. Uzel M, Sasmaz S, Bakaris S, Cetinus E, Bilgic E, Karaoguz A, et al. A viral infection of the hand commonly seen after the feast of sacrifice: human orf (orf of the hand). Epidemiol Infect. 2005 Aug. 133 (4):653-7. [View Abstract]
  24. Centers for Disease Control and Prevention. Orf Virus (Sore Mouth Infection). Available at http://www.cdc.gov/poxvirus/orf-virus/. May 11, 2015; Accessed: June 12, 2016.
  25. Turan E, Yesilova Y, Ucmak D. A case of orf (ecthyma contagiosum) with multiple lesions. J Pak Med Assoc. 2013 Jun. 63 (6):786-7. [View Abstract]
  26. Maor D, Yu LL, Brand R. A case of orf disease in a patient with scleroderma. JAAD Case Rep. 2017 Mar. 3 (2):155-157. [View Abstract]
  27. Georgiades G, Katsarou A, Dimitroglou K. Human ORF (ecthyma contagiosum). J Hand Surg Br. 2005 Aug. 30 (4):409-11. [View Abstract]
  28. Hsu CH, Rokni GR, Aghazadeh N, Brinster N, Li Y, Muehlenbachs A, et al. Unique Presentation of Orf Virus Infection in a Thermal-Burn Patient After Receiving an Autologous Skin Graft. J Infect Dis. 2016 Oct 15. 214 (8):1171-4. [View Abstract]
  29. Bodnar MG, Miller OF 3rd, Tyler WB. Facial orf. J Am Acad Dermatol. 1999 May. 40(5 Pt 2):815-7. [View Abstract]
  30. Ferrando MF, Léauté-Labrèze C, Fleury H, Taïeb A. Orf and erythema multiforme in a child. Pediatr Dermatol. 1997 Mar-Apr. 14(2):154-5. [View Abstract]
  31. Mourtada I, Le Tourneur M, Chevrant-Breton J, Le Gall F. [Human orf and erythema multiforme]. Ann Dermatol Venereol. 2000 Apr. 127(4):397-9. [View Abstract]
  32. Alian S, Ahangarkani F, Arabsheybani S. A Case of Orf Disease Complicated with Erythema Multiforme and Bullous Pemphigoid-Like Eruptions. Case Rep Infect Dis. 2015. 2015:105484. [View Abstract]
  33. Murphy JK, Ralfs IG. Bullous pemphigoid complicating human orf. Br J Dermatol. 1996 May. 134(5):929-30. [View Abstract]
  34. White KP, Zedek DC, White WL, Simpson EL, Hester E, Morrison L. Orf-induced immunobullous disease: A distinct autoimmune blistering disorder. J Am Acad Dermatol. 2008 Jan. 58(1):49-55. [View Abstract]
  35. Estela Cubells JR, Braverman I, Kashgarian M, Lazova R. A 65-Year-Old Female from Connecticut with Orf Infection. Dermatopathology (Basel). 2016 Apr-Jun. 3 (2):55-60. [View Abstract]
  36. Meier R, Sommacal A, Stahel A, Grünert J, Hoffmann M. Orf - an orphan disease?. JRSM Open. 2015 Jun. 6 (6):2054270415593718. [View Abstract]
  37. Taieb A, Guillot M, Carlotti D, Maleville J. Orf and pregnancy. Int J Dermatol. 1988 Jan-Feb. 27(1):31-3. [View Abstract]
  38. Chavez-Alvarez S, Barbosa-Moreno L, Villarreal-Martinez A, Vazquez-Martinez OT, Ocampo-Candiani J. Dermoscopy of contagious ecthyma (orf nodule). J Am Acad Dermatol. 2016 May. 74 (5):e95-6. [View Abstract]
  39. Ayhan E, Aktaş H. Dermoscopic features and types of orf and milker's nodule. Postepy Dermatol Alergol. 2017 Aug. 34 (4):357-362. [View Abstract]
  40. Centers for Disease Control and Prevention. Human orf mimicking cutaneous anthrax---California. MMWR. 1973. 22:108.
  41. Torfason EG, Gunadóttir S. Polymerase chain reaction for laboratory diagnosis of orf virus infections. J Clin Virol. 2002 Feb. 24(1-2):79-84. [View Abstract]
  42. Olson VA, Laue T, Laker MT, Babkin IV, Drosten C, Shchelkunov SN, et al. Real-time PCR system for detection of orthopoxviruses and simultaneous identification of smallpox virus. J Clin Microbiol. 2004 May. 42(5):1940-6. [View Abstract]
  43. Gallina L, Dal Pozzo F, Mc Innes CJ, Cardeti G, Guercio A, Battilani M, et al. A real time PCR assay for the detection and quantification of orf virus. J Virol Methods. 2006 Jun. 134(1-2):140-5. [View Abstract]
  44. Wang X, Zhang J, Hao W, Peng Y, Li H, Li W, et al. Isolation and Characterization of Monoclonal Antibodies Against a Virion Core Protein of Orf Virus Strain NA1/11 As Potential Diagnostic Tool for Orf Viruses. Monoclon Antib Immunodiagn Immunother. 2015 Aug. 34 (4):233-45. [View Abstract]
  45. Sanchez RL, Hebert A, Lucia H, Swedo J. Orf. A case report with histologic, electron microscopic, and immunoperoxidase studies. Arch Pathol Lab Med. 1985 Feb. 109(2):166-70. [View Abstract]
  46. Erbagci Z, Erbagci I, Almila Tuncel A. Rapid improvement of human orf (ecthyma contagiosum) with topical imiquimod cream: report of four complicated cases. J Dermatolog Treat. 2005. 16(5-6):353-6. [View Abstract]
  47. Lederman ER, Green GM, DeGroot HE, Dahl P, Goldman E, Greer PW, et al. Progressive ORF virus infection in a patient with lymphoma: successful treatment using imiquimod. Clin Infect Dis. 2007 Jun 1. 44(11):e100-3. [View Abstract]
  48. Ara M, Zaballos P, Sánchez M, Querol I, Zubiri ML, Simal E, et al. Giant and recurrent orf virus infection in a renal transplant recipient treated with imiquimod. J Am Acad Dermatol. 2008 Feb. 58(2 Suppl):S39-40. [View Abstract]
  49. Ran M, Lee M, Gong J, Lin Z, Li R. Oral Acyclovir and Intralesional Interferon Injections for Treatment of Giant Pyogenic Granuloma-Like Lesions in an Immunocompromised Patient With Human Orf. JAMA Dermatol. 2015 Sep. 151 (9):1032-4. [View Abstract]
  50. Ertekin SS, Gurel MS, Erdemir AVT, Leblebici C. Systemic interferon alfa injections for the treatment of a giant orf. Cutis. 2017 May. 99 (5):E19-E21. [View Abstract]
  51. Geerinck K, Lukito G, Snoeck R, De Vos R, De Clercq E, Vanrenterghem Y, et al. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J Med Virol. 2001 Aug. 64(4):543-9. [View Abstract]
  52. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin Microbiol Rev. 2003 Oct. 16(4):569-96. [View Abstract]
  53. Kilic SS, Puel A, Casanova JL. Orf Infection in a Patient with Stat1 Gain-of-Function. J Clin Immunol. 2015 Jan. 35 (1):80-3. [View Abstract]
  54. Degraeve C, De Coninck A, Senneseael J, Roseeuw D. Recurrent contagious ecthyma (Orf) in an immunocompromised host successfully treated with cryotherapy. Dermatology. 1999. 198(2):162-3. [View Abstract]
  55. Ocampo Candiani J, González Soto R, Welsh Lozano O. Orf nodule: treatment with cryosurgery. J Am Acad Dermatol. 1993 Aug. 29(2 Pt 1):256-7. [View Abstract]
  56. Shelley WB, Shelley ED. Surgical treatment of farmyard pox. Orf, milker's nodules, bovine papular stomatitis pox. Cutis. 1983 Feb. 31(2):191-2. [View Abstract]
  57. Sarma DP, Cox M, Walter P, Crisler W, Huerter C. A man with an umbilicated papule of the hand: what is your diagnosis?. Case Rep Med. 2010. 2010:524021. [View Abstract]

An early lesion of orf (papular stage).

A classic location of orf on the index finger.

An early lesion of orf (papular stage).

The target phase associated with edema.

The regenerative stage of orf with a central crust.

Orf lesion (arrow) associated with erythema multiforme.

An early lesion of orf (papular stage).

The target phase associated with edema.

A classic location of orf on the index finger.

The regenerative stage of orf with a central crust.

Orf lesion (arrow) associated with erythema multiforme.